文献速递炎症性肠病

系统综述与荟萃分析:维得利珠单抗谷浓度与炎症性肠病临床结局的关联

Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
PubMed 文献 · Aliment Pharmacol Ther · 2019-09-04

该系统综述与荟萃分析纳入截至2019年2月28日的5项队列研究(558例IBD患者,42%为溃疡性结肠炎),评估维得利珠单抗谷浓度与临床结局的关联。在UC患者中,达到临床或内镜缓解者的谷浓度显著更高;在CD患者中未见显著差异。UC患者第6周谷浓度≥18.5-20.8 μg/mL及维持期≥9.0-12.6 μg/mL与良好结局相关。

要点

  • UC患者达到临床或内镜缓解者维得利珠单抗谷浓度显著更高
  • CD患者中谷浓度与临床或内镜缓解无显著差异
  • UC第6周谷浓度≥18.5-20.8 μg/mL、维持期≥9.0-12.6 μg/mL与良好结局相关

核心结论

  • UC患者达到内镜和临床缓解者维持期维得利珠单抗谷浓度显著更高。
  • 第6周谷浓度>20 μg/mL及维持期>12 μg/mL可能与更好结局相关,但因果关系不明确。

研究设计与样本

  • 系统综述与荟萃分析,检索截至2019年2月28日,纳入5项队列研究共558例IBD患者(42%为UC)。

主要发现

  • UC临床缓解者中位谷浓度14.3 μg/mL vs 10.5 μg/mL,MD 5.1 μg/mL(95%CI 2.8-7.4)。
  • UC内镜缓解者中位谷浓度13.0 μg/mL vs 9.7 μg/mL,MD 5.1 μg/mL(95%CI 2.2-7.9)。
  • CD临床缓解MD 2.0 μg/mL(95%CI -0.5至4.5),内镜缓解MD 3.6 μg/mL(95%CI -1.4至8.6),均无显著差异。
  • 维持治疗中抗维得利珠单抗抗体报告率为1.7%-3.0%。

关键数值与推荐

  • UC第6周谷浓度≥18.5-20.8 μg/mL与良好临床结局相关。
  • UC维持期谷浓度≥9.0-12.6 μg/mL与良好临床结局相关。

临床怎么用

  • 对UC患者可考虑监测维得利珠单抗谷浓度以辅助评估临床结局。
  • 第6周及维持期谷浓度阈值可作为参考,但需前瞻性研究验证因果。

局限性

  • 纳入研究均为队列研究,无法确立因果关系。
  • 样本量有限(558例),CD患者结果不显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There has been limited evaluation of the association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases (IBD). AIM: To perform a systematic review and meta-analysis to evaluate the potential role of therapeutic drug monitoring (TDM) for vedolizumab. METHODS: Through a systematic literature search through 28 February 2019, we identified five cohort studies (558 patients, 42% with ulcerative colitis) reporting the association between vedolizumab trough concentration and clinical outcomes in patients with IBD. We calculated mean difference (MD) in vedolizumab trough concentration in patients achieving vs not achieving clinical outcomes, and qualitatively synthesized thresholds associated with favourable outcomes. RESULTS: In patients with UC, median vedolizumab trough concentrations were consistently higher in patients achieving clinical remission (median, 14.3 μg/mL vs 10.5 μg/mL; MD, 5.1 μg/mL, 95% CI, 2.8-7.4) or endoscopic remission (median, 13.0 μg/mL vs 9.7; MD, 5.1 μg/mL, 95% CI, 2.2-7.9). In patients with CD, there was no significant difference in median vedolizumab trough concentrations in patients achieving vs not achieving clinical remission (MD, 2.0 μg/mL; 95% CI, -0.5 to 4.5) or endoscopic remission (MD, 3.6 μg/mL; 95% CI, -1.4 to 8.6). In patients with UC, week 6 vedolizumab trough concentrations ≥18.5-20.8 μg/mL, and maintenance trough concentrations ≥9.0-12.6 μg/mL were associated with favourable clinical outcomes. Antibodies to vedolizumab were reported in 1.7%-3.0% patients on maintenance therapy. CONCLUSION: Based on meta-analysis, patients with UC who achieve endoscopic and clinical remission have significantly higher vedolizumab trough concentration during maintenance therapy. Vedolizumab trough concentration >20 μg/mL at week 6, and >12 μg/mL during maintenance may be associated with better outcomes, though cause-effect relationship remains unclear. Prospective studies on reactive and proactive therapeutic drug monitoring of vedolizumab (vs empiric dose escalation) are warranted.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Singh S, Dulai PS, Vande Casteele N, et al. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019. PMID: 31483522. doi:10.1111/apt.15484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。